Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

1.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

PMID:
23875536
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).

Arnould L, Roger P, Macgrogan G, Chenard MP, Balaton A, Beauclair S, Penault-Llorca F.

Mod Pathol. 2012 May;25(5):675-82. doi: 10.1038/modpathol.2011.201. Epub 2012 Jan 6.

PMID:
22222637
[PubMed - indexed for MEDLINE]
Free Article
3.

Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.

Francis GD, Jones MA, Beadle GF, Stein SR.

Diagn Mol Pathol. 2009 Jun;18(2):88-95. doi: 10.1097/PDM.0b013e31816f6374.

PMID:
19430296
[PubMed - indexed for MEDLINE]
4.

Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.

Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B.

Histopathology. 2009 Jan;54(2):248-53. doi: 10.1111/j.1365-2559.2008.03185.x.

PMID:
19207950
[PubMed - indexed for MEDLINE]
5.

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.

Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J.

Br J Cancer. 2003 May 19;88(10):1587-91.

PMID:
12771927
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.

Koh YW, Lee HJ, Lee JW, Kang J, Gong G.

Mod Pathol. 2011 Jun;24(6):794-800. doi: 10.1038/modpathol.2011.9. Epub 2011 Feb 11.

PMID:
21317877
[PubMed - indexed for MEDLINE]
Free Article
7.

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.

Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.

Mod Pathol. 2002 Jun;15(6):657-65.

PMID:
12065780
[PubMed - indexed for MEDLINE]
Free Article
8.

Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.

Wixom CR, Albers EA, Weidner N.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):248-51.

PMID:
15551739
[PubMed - indexed for MEDLINE]
9.

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).

Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H.

Pathol Int. 2012 Nov;62(11):728-34. doi: 10.1111/j.1440-1827.2012.02862.x.

PMID:
23121603
[PubMed - indexed for MEDLINE]
10.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

PMID:
17922920
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).

Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY.

Pathol Int. 2010 Jul;60(7):510-5. doi: 10.1111/j.1440-1827.2010.02553.x.

PMID:
20594272
[PubMed - indexed for MEDLINE]
12.

Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.

Li-Ning-T E, Ronchetti R, Torres-Cabala C, Merino MJ.

Int J Surg Pathol. 2005 Oct;13(4):343-51.

PMID:
16273190
[PubMed - indexed for MEDLINE]
13.
14.

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S, Loening T, Pantel K.

J Cancer Res Clin Oncol. 2011 Feb;137(2):261-9. doi: 10.1007/s00432-010-0881-0. Epub 2010 Apr 16.

PMID:
20396915
[PubMed - indexed for MEDLINE]
15.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120
[PubMed - indexed for MEDLINE]
16.

Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.

Dandachi N, Dietze O, Hauser-Kronberger C.

Lab Invest. 2002 Aug;82(8):1007-14.

PMID:
12177239
[PubMed - indexed for MEDLINE]
17.

Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.

Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, Morey A, Bilous M, Nagle R, Prescott N, Wang L, Dragovich L, McElhinny A, Garcia CF, Ranger-Moore J, Free H, Powell W, Loftus M, Pettay J, Gaire F, Roberts C, Dietel M, Roche P, Grogan T, Tubbs R.

Am J Surg Pathol. 2010 Jun;34(6):767-76. doi: 10.1097/PAS.0b013e3181d96231.

PMID:
20421783
[PubMed - indexed for MEDLINE]
18.

[Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].

Zhang GH, Shi DR, Liang XM, Hou JH, Kang SY, Zhu WD, Li XB, Shao Y, Chen LR, Zhou Y.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):580-3. Chinese.

PMID:
17134562
[PubMed - indexed for MEDLINE]
19.

Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.

Hauser-Kronberger C, Dandachi N.

J Mol Histol. 2004 Aug;35(6):647-53.

PMID:
15614619
[PubMed - indexed for MEDLINE]
20.

[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].

Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Chinese.

PMID:
17134563
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk